142 related articles for article (PubMed ID: 28164348)
21. Methotrexate for induction of remission in refractory Crohn's disease.
Alfadhli AA; McDonald JW; Feagan BG
Cochrane Database Syst Rev; 2005 Jan; (1):CD003459. PubMed ID: 15674908
[TBL] [Abstract][Full Text] [Related]
22. Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials.
Cholapranee A; Hazlewood GS; Kaplan GG; Peyrin-Biroulet L; Ananthakrishnan AN
Aliment Pharmacol Ther; 2017 May; 45(10):1291-1302. PubMed ID: 28326566
[TBL] [Abstract][Full Text] [Related]
23. Systematic review with meta-analysis: prevalence, risk factors and costs of aminosalicylate use in Crohn's disease.
Ma C; Dutton SJ; Cipriano LE; Singh S; Parker CE; Nguyen TM; Guizzetti L; Gregor JC; Chande N; Hindryckx P; Feagan BG; Jairath V
Aliment Pharmacol Ther; 2018 Jul; 48(2):114-126. PubMed ID: 29851091
[TBL] [Abstract][Full Text] [Related]
24. Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data.
Schreiber S; Colombel JF; Bloomfield R; Nikolaus S; Schölmerich J; Panés J; Sandborn WJ;
Am J Gastroenterol; 2010 Jul; 105(7):1574-82. PubMed ID: 20234346
[TBL] [Abstract][Full Text] [Related]
25. Has the therapeutical ceiling been reached in Crohn's disease randomized controlled trials? A systematic review and meta-analysis.
Magro F; Moreira PL; Catalano G; Alves C; Roseira J; Estevinho MM; Silva I; Dignass A; Peyrin-Biroulet L; Danese S; Jairath V; Dias CC; Santiago M
United European Gastroenterol J; 2023 Mar; 11(2):202-217. PubMed ID: 36876515
[TBL] [Abstract][Full Text] [Related]
26. Placebo response rate in clinical trials of fistulizing Crohn's disease: systematic review and meta-analysis.
Ford AC; Luthra P; Hanauer SB; Travis SP; Harris MS; Reinisch W
Clin Gastroenterol Hepatol; 2014 Dec; 12(12):1981-90. PubMed ID: 25218669
[TBL] [Abstract][Full Text] [Related]
27. Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials.
Panés J; Sandborn WJ; Schreiber S; Sands BE; Vermeire S; D'Haens G; Panaccione R; Higgins PDR; Colombel JF; Feagan BG; Chan G; Moscariello M; Wang W; Niezychowski W; Marren A; Healey P; Maller E
Gut; 2017 Jun; 66(6):1049-1059. PubMed ID: 28209624
[TBL] [Abstract][Full Text] [Related]
28. Vedolizumab as induction and maintenance therapy for Crohn's disease.
Sandborn WJ; Feagan BG; Rutgeerts P; Hanauer S; Colombel JF; Sands BE; Lukas M; Fedorak RN; Lee S; Bressler B; Fox I; Rosario M; Sankoh S; Xu J; Stephens K; Milch C; Parikh A;
N Engl J Med; 2013 Aug; 369(8):711-21. PubMed ID: 23964933
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease.
Rutgeerts P; Gasink C; Chan D; Lang Y; Pollack P; Colombel JF; Wolf DC; Jacobstein D; Johanns J; Szapary P; Adedokun OJ; Feagan BG; Sandborn WJ
Gastroenterology; 2018 Oct; 155(4):1045-1058. PubMed ID: 29909019
[TBL] [Abstract][Full Text] [Related]
30. Impact of Crohn's Disease Therapies on Histology in Randomized Controlled Trials: Systematic Review With Meta-analysis.
Roseira J; Santiago M; Estevinho MM; Moreira P; Alves C; Danese S; Peyrin-Biroulet L; Dignass A; Feakins R; Magro F
Inflamm Bowel Dis; 2023 Aug; 29(8):1231-1243. PubMed ID: 36250778
[TBL] [Abstract][Full Text] [Related]
31. Vedolizumab for induction and maintenance of remission in ulcerative colitis.
Bickston SJ; Behm BW; Tsoulis DJ; Cheng J; MacDonald JK; Khanna R; Feagan BG
Cochrane Database Syst Rev; 2014 Aug; (8):CD007571. PubMed ID: 25105240
[TBL] [Abstract][Full Text] [Related]
32. Maintenance of clinical remission with biologics and small molecules in inflammatory bowel disease according to trial design: Meta-analysis.
Barberio B; Gracie DJ; Black CJ; Ford AC
Dig Liver Dis; 2024 Jan; 56(1):7-14. PubMed ID: 37357037
[TBL] [Abstract][Full Text] [Related]
33. Ustekinumab induction and maintenance therapy in refractory Crohn's disease.
Sandborn WJ; Gasink C; Gao LL; Blank MA; Johanns J; Guzzo C; Sands BE; Hanauer SB; Targan S; Rutgeerts P; Ghosh S; de Villiers WJ; Panaccione R; Greenberg G; Schreiber S; Lichtiger S; Feagan BG;
N Engl J Med; 2012 Oct; 367(16):1519-28. PubMed ID: 23075178
[TBL] [Abstract][Full Text] [Related]
34. Enteral nutritional therapy for inducing remission of Crohn's disease.
Zachos M; Tondeur M; Griffiths AM
Cochrane Database Syst Rev; 2001; (3):CD000542. PubMed ID: 11686966
[TBL] [Abstract][Full Text] [Related]
35. Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn's disease: a network meta-analysis.
Hazlewood GS; Rezaie A; Borman M; Panaccione R; Ghosh S; Seow CH; Kuenzig E; Tomlinson G; Siegel CA; Melmed GY; Kaplan GG
Gastroenterology; 2015 Feb; 148(2):344-54.e5; quiz e14-5. PubMed ID: 25448924
[TBL] [Abstract][Full Text] [Related]
36. Comparative Effectiveness of Mesalamine, Sulfasalazine, Corticosteroids, and Budesonide for the Induction of Remission in Crohn's Disease: A Bayesian Network Meta-analysis.
Coward S; Kuenzig ME; Hazlewood G; Clement F; McBrien K; Holmes R; Panaccione R; Ghosh S; Seow CH; Rezaie A; Kaplan GG
Inflamm Bowel Dis; 2017 Mar; 23(3):461-472. PubMed ID: 28146003
[TBL] [Abstract][Full Text] [Related]
37. Systematic Review and Meta-analysis: Adalimumab Monotherapy Versus Combination Therapy with Immunomodulators for Induction and Maintenance of Remission and Response in Patients with Crohn's Disease.
Chalhoub JM; Rimmani HH; Gumaste VV; Sharara AI
Inflamm Bowel Dis; 2017 Aug; 23(8):1316-1327. PubMed ID: 28719541
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of certolizumab pegol for Crohn's disease: a systematic review and meta-analysis.
Da W; Zhu J; Wang L; Lu Y
Adv Ther; 2013 May; 30(5):541-53. PubMed ID: 23681504
[TBL] [Abstract][Full Text] [Related]
39. Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease.
Schreiber S; Reinisch W; Colombel JF; Sandborn WJ; Hommes DW; Robinson AM; Huang B; Lomax KG; Pollack PF
J Crohns Colitis; 2013 Apr; 7(3):213-21. PubMed ID: 22704916
[TBL] [Abstract][Full Text] [Related]
40. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's Disease.
Akobeng AK; Gardener E
Cochrane Database Syst Rev; 2005 Jan; (1):CD003715. PubMed ID: 15674913
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
